Finland - February 10, 2026
Private funding boosts transformative research in Alzheimer’s in Finland
A private foundation has made a significant donation to the University of Helsinki to accelerate research on neurodegenerative diseases at the Institute for Molecular Medicine Finland (FIMM).
Clinical Trials - February 10, 2026
Lundbeck presents real-world data highlighting improvements in migraine
The company has announced six-month data from the 12-month, real-world INFUSE study, evaluating the effectiveness of Vyepti in adults with migraine who had failed at least one preventive anti-calcitonin gene–related peptide (aCGRP) treatment, at any time point previously.
Science News - February 10, 2026
Nordic study maps KRAS and NRAS in metastatic colorectal cancer
Data from Finnish and Swedish cohorts link specific RAS mutation subtypes to distinct treatment outcomes, strengthening the evidence base for biomarker‑guided therapy.
Digital health - February 10, 2026
Europe: Digital Medicines Information gains momentum
Europe is moving towards a digital future for medicines information, a new report from AESGP, EFPIA and Medicines for Europe shows.
Legal Advice article - February 10, 2026
Novo Nordisk sues Hims & Hers over alleged unsafe Wegovy and Ozempic knock‑offs
On 9 February 2026, Novo Nordisk announced it has filed a lawsuit against U.S. telehealth company Hims & Hers, alleging that the firm is offering compounded, non‑FDA‑approved versions of Wegovy and Ozempic that could put patients at risk.
Acquisition - February 9, 2026
Lilly to acquire Orna Therapeutics to advance cell therapies
Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell therapies that can treat underlying disease.
